Using oral minoxidil to treat recurrent platinum resistant ovarian cancer
A Phase II Trial of Oral Minoxidil for the Treatment of Recurrent Platinum Resistant Epithelial Ovarian Cancer
This study is testing if a medication called oral minoxidil can help people with recurrent platinum-resistant ovarian cancer feel better and slow down the disease.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Enrollment | 34 (estimated) |
| Ages | 18 Years to 90 Years |
| Sex | Female |
| Sponsor | Loyola University Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Maywood, Illinois) |
| Trial ID | NCT05272462 on ClinicalTrials.gov |
What this trial studies
This study aims to evaluate the effectiveness of oral minoxidil in patients with recurrent platinum resistant epithelial ovarian cancer. The primary focus is to determine the response rate to minoxidil treatment, while secondary objectives include assessing the time to disease progression and documenting any associated toxicities. Additionally, the study will explore whether the efficacy of minoxidil is enhanced in patients with the Kir6/SUR complex. The study builds on previous findings that suggest minoxidil may disrupt cancer cell division and promote tumor reduction.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older with recurrent platinum resistant ovarian cancer.
Not a fit: Patients with brain metastases, significant cardiac issues, or those currently undergoing other treatments may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could provide a new therapeutic option for patients with limited responses to existing ovarian cancer treatments.
How similar studies have performed: While this approach is novel in the context of ovarian cancer, previous studies have shown promising results with minoxidil in other cancer models.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria * Participants must have recurrent platinum resistant ovarian cancer. Histologic documentation of the recurrence is not required. * Participants must have platinum resistant disease defined as recurrence less than 6 months after initial platinum based treatment. * Participants must be greater than or equal to 18 years of age. * Participants must have an Eastern Cooperative Group (ECOG) Performance Status (PS) less than or equal to 2. * Participants must be able to take oral medications. Exclusion Criteria * Participants must not have had chemotherapy or radiotherapy within 4 weeks * Participants must not be receiving any other investigational agents. * Participants must not have brain metastases * Participants must not have allergic reactions to minoxidil * Participants must not have congestive heart failure * Participants must not have history of cardiac disease * Participants must not have uncontrolled hypertension * Participants must not be on dialysis
Where this trial is running
Maywood, Illinois
- Loyola University Medical Center — Maywood, Illinois, United States (Recruiting)
Study contacts
- Principal investigator: Margaret Liotta, DO — Loyola University
- Study coordinator: Margaret Liotta, DO
- Email: mliotta@lumc.edu
- Phone: 708-216-5423
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.